Core Viewpoint - Galectin Therapeutics Inc. has secured a new $10 million unsecured line of credit from Richard E. Uihlein, the Chairman and largest individual stockholder, to support its MASH cirrhosis program and ongoing operations [1][2]. Financial Details - The new credit line allows borrowings at the company's discretion until April 30, 2026, with an interest rate of 6.05% (4.05% plus 2%) [2]. - Principal and interest are due on September 30, 2026, and can be converted into shares at a minimum price of $3.00 per share [2]. - Up to 200,000 stock purchase warrants will be issued to Mr. Uihlein, with exercise prices ranging from $3.00 to $10.00 per share [2]. Existing Financial Obligations - The maturity dates for three existing $10 million convertible notes payable to Mr. Uihlein and $81 million in borrowings under other lines of credit have been extended to September 30, 2026 [3]. Company Strategy and Development - The financing is expected to cover projected expenditures through June 2026, allowing the company to focus on its NAVIGATE trial and potential FDA presentations [4]. - The company is actively seeking partnerships to support the development and commercialization of its lead drug, belapectin, for MASH cirrhosis and portal hypertension [4][5]. Product Information - Galectin Therapeutics is focused on developing therapies for chronic liver disease and cancer, with belapectin being its lead drug targeting galectin-3, which is involved in various diseases [5]. - The company has received Fast Track designation from the FDA for belapectin, which is aimed at treating MASH cirrhosis, a significant unmet medical need [5].